Clinical Application of CAR T Cells 2019

Clinical Application of CAR T Cells 2019 Banner


Date & Location
Thursday, March 14, 2019, 8:00 AM - Friday, March 15, 2019, 6:00 PM, Zuckerman Research Center, 417 East 68th Street, New York, NY

Specialties
Allergy & Immunology, Gynecologic Oncology, Head and Neck Oncology, Hematology, Hematology & Oncology, Industry, Leukemia, Lymphoma, Medical Oncology, Pediatric Oncology, Pulmonary Medicine, Thoracic Medical Oncology

Overview

Chimeric antigen receptor (CAR) T-cell ("Living Drug") immunotherapy is showing promising results in the treatment of cancers. There are nine ongoing clinical trials (Phase I & II) at Memorial Sloan Kettering (MSK) and more are on track to be initiated next year. Over the years, MSK has accumulated a breadth of knowledge about developing and translating these clinical trials from bench to bedside and back to bench – constructing, manufacturing and obtaining FDA approvals for clinical grade CARs and vectors, developing universal algorithms across multiple CAR T-cell clinical trials for the treatment and management of complications, and conducting world-class correlative science.

MSK faculty, along with national and international experts, will discuss the clinical and translational aspects of cell therapies (CARs, TCRs, NKs), both for hematologic malignancies and solid tumors.

The target audience includes medical oncologists and oncology fellows, basic scientists, research fellows, nurses, clinical trial research staff, immunologists, and surgeons with an interest in tumor immunology and immunotherapy.

Keynote Speakers

Carl H. June, MD
University of Pennsylvania

Michel Sadelain, MD, PhD
Memorial Sloan Kettering Cancer Center

MSK Course Director

Prasad S. Adusumilli, MD, FACS, FCCP
Deputy Chief, Thoracic Surgery Service, Department of Surgery
Director, Mesothelioma Program
Head, Solid Tumors Cell therapy, Center for Cellular Therapeutics
Member, Center for Cell Engineering 

MSK Course Co-Directors

Renier J. Brentjens, MD, PhD
Director, Cellular Therapeutics Center
Member, Leukemia Service
Division of Hematologic Oncology
Department of Medicine

Michel Sadelain, MD, PhD
Director, Center for Cell Engineering
Member, Immunology Program
Member, Departments of Medicine and Pediatrics

Main Sessions Topics

  • Mechanisms of Relapse and Toxicity in CD19 CAR T-cell Therapies
  • TCRs and TILs
  • CARS for Myeloma
  • The Ins and Outs of Manufacturing Engineering Cells
  • Building a Clinical CAR T-cell Program
  • Novel Cell Therapies
  • Solid Tumor Cell Therapies
  • ABC of Cell Therapy for Paramedical Staff - Attendees will learn the basics of cellular therapy including the pre-clinical development, clinical translation, and regulatory requirements from medical, para-medical, nursing, and research experts involved in cellular therapy clinical trials. In addition, the essentials of designing and conducting a cell therapy clinical trial will be presented. Attendees will have opportunity to visit cell therapy lab(s), manufacturing facility, and apheresis unit involved in the investigational and commercial application of cellular therapies. At the end of the session, registered attendees will have opportunity to interact one-on-one with cell therapy experts.

Meet the experts session

Attendees will have an opportunity to interact, discuss and learn from Cell Therapy Faculty in an informal dialogue. Please choose the round table session you like to participate in at registration. Options include Neurotoxicity, ICU management, CRS, Manufacturing QA & QC, Solid tumor cell therapy, TCRs, Multi-center trials, Anti-PD1 strategies post cell therapy, Commercial CART T cells, or Role of Nursing.

Optional Non-CME Industry Sessions

There will be two optional non-CME industry sessions for attendees, one on Thursday from 4:30-6:00 pm and another on Friday from 5:00-5:30 pm. Please note that Memorial Sloan Kettering Cancer Center will not be offering CME credits for either industry session.
View the industry session agendas.

Call for Abstracts

Participants are invited to submit an abstract for presentation at the course. Abstracts for the poster session will be selected on the basis of scientific merit and content quality. Presenting author(s) of selected abstracts will be notified of presentation either at the poster session or as mini-oral presentation in the main program. To submit an abstract for presentation, please select 'Abstracts' above. Submission Deadline: March 13, 2019.


Objectives
  1. Participants will be able to have an understanding of current CD19 CAR T-cell therapy outcomes and limitations.
  2. Participants will be able to familiarize the onset, optimal management and the results on anti-tumor efficacy of CAR T-cell toxicities
  3. To learn clinical management of patients participating in phase I clinical trials

Registration

This course is sold out,

Unfortunately, we will not be able to accommodate onsite registrations.

 Academia Fees     
 Physicians (MDs, PhDs and DOs)
  $600 
 Residents, Fellows, Nurses and Other Healthcare Providers     
  $300 
 Industry Fees*
 All Members (any employee working for a commercial interest**)       $1,500 

*Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities. The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. Please click here for more information or email cme@mskcc.org if you have additional questions.

Course registration includes continental breakfast, lunch, and refreshment breaks. Please contact cme@mskcc.org at least one week prior to the course if you have any special dietary requests or require any specific accommodations.

Registration Discounts/Promotions

  • MSK CME offers a 30% discounted rate for MSK Alumni, MSK Cancer Alliance and Cancer Care Partners. If you are a member of one of these groups, please contact cme@mskcc.org for more information.
  • MSK Employee Registration Waitlist. MSK staff interested in registering for this course should join the waitlist. We will notify you before the course if space is available.

Please note: after your payment has been processed, no further promotional discount adjustments will be made to your registration.

Cancellation Policy

If you cancel your participation in this course, your registration fee, less a $75 administrative fee, will be refunded when email notification is received by the MSK Office of Continuing Medical Education (MSK CME) at least 7 days prior to the first day of the course (cme@mskcc.org).

Cancellations or no-shows after this date are not eligible for a refund. MSK CME reserves the right to cancel or postpone any course due to unforeseen circumstances. In the unlikely event we must cancel or postpone this course, we will refund the registration fee in full, but are not responsible for any related costs, charges, or expenses to participants, including fees incurred by airline/travel/lodging agencies. At any time, you may substitute another registrant in your place after contacting MSK CME with the relevant information.


Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

MSK designates this live activity for a maximum of 16.25 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

CME hours from this conference qualify for the Federation for the Accreditation of Cellular Therapy (FACT) Immune Effector Cells (IEC) annual training requirement (10 hrs needed).